Greenleaf Trust lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 7.3% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 27,910 shares of the company’s stock after acquiring an additional 1,910 shares during the period. Greenleaf Trust’s holdings in Novo Nordisk A/S were worth $1,316,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of NVO. Renaissance Technologies LLC raised its stake in shares of Novo Nordisk A/S by 12.0% during the 2nd quarter. Renaissance Technologies LLC now owns 19,142,300 shares of the company’s stock worth $882,843,000 after buying an additional 2,051,000 shares during the period. Fisher Asset Management LLC raised its stake in Novo Nordisk A/S by 1.7% in the 3rd quarter. Fisher Asset Management LLC now owns 13,797,404 shares of the company’s stock valued at $650,410,000 after purchasing an additional 227,733 shares during the last quarter. Northern Trust Corp raised its stake in Novo Nordisk A/S by 2.2% in the 2nd quarter. Northern Trust Corp now owns 2,093,244 shares of the company’s stock valued at $96,540,000 after purchasing an additional 45,725 shares during the last quarter. Wells Fargo & Company MN raised its stake in Novo Nordisk A/S by 14.0% in the 2nd quarter. Wells Fargo & Company MN now owns 1,301,934 shares of the company’s stock valued at $60,046,000 after purchasing an additional 159,619 shares during the last quarter. Finally, Aperio Group LLC raised its stake in Novo Nordisk A/S by 3.2% in the 3rd quarter. Aperio Group LLC now owns 1,088,502 shares of the company’s stock valued at $51,312,000 after purchasing an additional 34,088 shares during the last quarter. Institutional investors and hedge funds own 6.85% of the company’s stock.
Several research firms recently commented on NVO. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, July 31st. ValuEngine downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. Cfra reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Friday, November 2nd. Guggenheim assumed coverage on Novo Nordisk A/S in a research note on Monday, October 8th. They issued a “buy” rating for the company. Finally, Pareto Securities downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $64.00.
Shares of NYSE NVO traded up $0.60 during mid-day trading on Thursday, reaching $44.24. 816,855 shares of the company’s stock were exchanged, compared to its average volume of 1,473,106. The stock has a market cap of $106.64 billion, a PE ratio of 18.91, a P/E/G ratio of 2.31 and a beta of 0.76. Novo Nordisk A/S has a 52-week low of $41.23 and a 52-week high of $58.37.
Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Thursday, November 1st. The company reported $0.58 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.58. The business had revenue of $4.31 billion during the quarter, compared to analysts’ expectations of $4.11 billion. Novo Nordisk A/S had a return on equity of 81.50% and a net margin of 34.94%. Analysts expect that Novo Nordisk A/S will post 2.44 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://theenterpriseleader.com/2018/11/22/novo-nordisk-a-s-nvo-shares-bought-by-greenleaf-trust.html.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.
See Also: What is a balanced fund?
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.